WO2011162421A2 - 発泡型皮膚外用剤 - Google Patents
発泡型皮膚外用剤 Download PDFInfo
- Publication number
- WO2011162421A2 WO2011162421A2 PCT/JP2011/071734 JP2011071734W WO2011162421A2 WO 2011162421 A2 WO2011162421 A2 WO 2011162421A2 JP 2011071734 W JP2011071734 W JP 2011071734W WO 2011162421 A2 WO2011162421 A2 WO 2011162421A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- skin
- mass
- foam
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
Definitions
- the present invention relates to a skin external preparation having excellent foamability and carbon dioxide retention in a foam type skin external preparation that generates carbon dioxide.
- Carbon dioxide is known to have a vasodilatory effect and is clinically used for rehabilitation as a carbon dioxide bath.
- a pack agent using carbon dioxide gas generated by mixing carbonate and acid is also known in skin care preparations (Patent Document 1).
- a viscous composition composed of a water-soluble thickener such as an alginate or sodium carboxymethylcellulose containing carbonate and a water-soluble acid mixed immediately before use to give a viscosity in advance
- a method of reducing escape by generating carbon dioxide in the material is known (Patent Document 2).
- the composition becomes a paste, so carbon dioxide gas when mixed with a water-soluble acid It was difficult to visually appeal to the user that carbon dioxide gas was generated.
- the amount of carbon dioxide gas is increased by changing the type of carbonate or water-soluble acid, it can be visually informed that carbon dioxide gas is generated, but the composition of the generated gas In some cases, the viscosities of these products drastically decrease, causing drooping from the skin during use or soiling clothes.
- the object of the present invention is to balance the foaming amount / holding power of carbon dioxide gas that appeals to the user's vision and good usability such as prevention of dripping from the skin, which could not be easily obtained with conventional foam-type external skin preparations
- Another object of the present invention is to provide a foamed skin external preparation.
- the present inventor has examined the above-mentioned problems, and by using a hydrophobized modified alkyl cellulose, a foam-type skin external preparation having excellent carbon dioxide foam retention and improved usability such as prevention of dripping from the skin.
- the technology to be provided was found and the present invention was completed.
- the present invention provides the following foam-type external skin preparation.
- Item 1. A foam-type external preparation for skin containing hydrophobically modified alkyl cellulose as an essential component.
- Item 2. Item 2.
- Item 3. The hydrophobically modified alkyl cellulose is The following structural formula (1):
- R 1 , R 2 and R 3 are the same or different and each represents a hydrogen atom, a lower alkyl group, Groups: - [CH 2 CH 2- k (CH 3) k O] m H, Or the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 .
- n is an integer of 100 to 10,000, k is an integer of 0 or 1, m is an integer of 1 to 10, j represents an integer of 6 to 26.
- the hydrophobized modified alkylcellulose necessarily comprises the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 , Item 3.
- the foamed skin external preparation according to Item 1 or 2.
- Hydrophobized modified alkyl cellulose represented by the structural formula (1)
- Item 4 The foamable external skin preparation according to Item 3, comprising Item 5.
- the foamable skin external preparation according to Item 3 or 4 wherein the value of j of the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 contained in the structural formula (1) is 18.
- Item 6. Item 6.
- Item 7. Item 7. The foamable external preparation for skin according to any one of Items 2 to 6, wherein the water-soluble acid is a hydroxy acid.
- Item 8. Item 8. The foamable external skin preparation according to Item 7, wherein the hydroxy acid is citric acid.
- Item 9. Item 9. The foamable skin external preparation according to any one of Items 1 to 8, wherein the foamable external skin preparation further contains a polyhydric alcohol.
- the item described above, wherein the polyhydric alcohol comprises one or more selected from the group consisting of propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 1,2-pentanediol.
- the foam-type external skin preparation according to 9. Item 11.
- the foam-type external preparation for skin is prepared by separating agent A containing at least one salt selected from the group consisting of carbonates and bicarbonates and agent B containing a water-soluble acid, which are mixed at the time of use.
- agent B containing a water-soluble acid
- hydrophobically modified alkyl cellulose as an essential component, it is possible to satisfy both the foaming amount and holding power of carbon dioxide gas and good usability such as prevention of dripping from the skin.
- the foamed external preparation for skin of the present invention contains hydrophobically modified alkyl cellulose as an essential component.
- the carbon dioxide gas has excellent foam retention and can improve the feeling of use such as prevention of dripping from the skin.
- the foam-type external skin preparation of the present invention preferably contains a hydrophobized modified alkyl cellulose; at least one salt selected from the group consisting of carbonates and bicarbonates; and a water-soluble acid.
- hydrophobized modified alkyl cellulose at least one salt selected from the group consisting of carbonates and bicarbonates; and water-soluble acids will be described.
- hydrophobized modified alkyl cellulose used in the foamed skin external preparation of the present invention is obtained by introducing a long-chain alkyl group, which is a hydrophobic group, into a cellulose ether derivative.
- the hydrophobically modified alkyl cellulose has the following structural formula (1):
- R 1 , R 2 and R 3 are the same or different and each represents a hydrogen atom, a lower alkyl group, Groups: - [CH 2 CH 2- k (CH 3) k O] m H, Or the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 .
- n is an integer of 100 to 10,000, k is an integer of 0 or 1, m is an integer of 1 to 10, j represents an integer of 6 to 26.
- the hydrophobized modified alkyl cellulose necessarily contains the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 .
- Hydroxypropylmethylcellulose means that in the structural formula (1), R 1 , R 2 and R 3 are the same or different and are —H, —CH 3 or a group: — [CH 2 CH (CH 3 ) O] m H, including the group — [CH 2 CH (CH 3 ) O] m H.
- Hydrophobized modified alkylcellulose is a product in which a long-chain alkyl group is introduced into HPMC.
- a long-chain alkyl group is introduced into HPMC.
- an alkali catalyst stearyl glycidyl ether:
- cetyl glycidyl ether and decyl glycidyl ether may be used.
- the hydrophobically modified alkyl cellulose represented by the structural formula (1) preferably contains 0.1 to 10.0% by mass of a group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 , More preferably, it is contained in an amount of ⁇ 2.0% by mass, particularly preferably 0.1-1.0% by mass.
- the content of C j H 2j + 1 in the group: —CH 2 CH (OH) CH 2 OC j H 2j + 1 exceeds 10.0% by mass in the hydrophobized modified alkyl cellulose, the solubility in water decreases and the dissolved product Tends to be cloudy, and there is a high possibility that the final product does not have sufficient viscosity effective for foam retention.
- the lower alkyl group contained in the hydrophobically modified alkyl cellulose represented by the structural formula (1) is preferably a methyl group, an ethyl group, or the like, and more preferably a methyl group.
- the hydrophobized modified alkylcellulose represented by the structural formula (1) preferably contains 10.0 to 50.0% by mass of a methyl group because of its good solubility in water. More preferably, the content is ⁇ 30.0% by mass.
- the group:-[CH 2 CH 2-k (CH 3 ) k O] m H contained in the hydrophobically modified alkyl cellulose represented by the structural formula (1) is a group:-[ CH 2 CH 2 O] m H, and when k is 1, the group: — [CH 2 CH (CH 3 ) O] m H. Particularly preferred is a group when k is 1: — [CH 2 CH (CH 3 ) O] m H.
- the hydrophobized modified alkylcellulose represented by the structural formula (1) has a group: — [CH 2 CH (CH 3 ) O] m H of 3.0 to 20.0 mass from the viewpoint of solubility in water. %, Preferably 7.0 to 11.0% by mass.
- the content of 2j + 1 is a value measured by a method according to the section of the 13th revised Japanese Pharmacopoeia hydroxypropylmethylcellulose 2208.
- hydrophobized modified alkyl cellulose satisfying these conditions, a trade name: Sangelose manufactured by Daido Kasei Kogyo Co., Ltd. can be preferably exemplified.
- the blending amount of the hydrophobized modified alkylcellulose used in the foamable external skin preparation of the present invention is preferably 0.1 to 10.0% by mass, more preferably 0.5 to 0.5%, based on the total amount of the foamable external skin preparation. 5.0% by mass.
- the blending amount of the hydrophobized modified alkyl cellulose with respect to the total amount of the foam-type external preparation for skin is less than 0.1% by mass, there is a tendency that the final product has a sufficient thickening effect and an effect on carbon dioxide (foam) retention.
- the content exceeds 10.0% by mass the viscosity becomes so high that it is difficult to mix at the time of use, it is difficult to apply to the skin, and the production of the product itself is hindered.
- each component while expressing with the mixture ratio (mass%) with respect to foam type skin external preparation whole quantity (or each form), it represents with the compounding quantity (mass part) with respect to 100 mass parts of hydrophobic modification alkyl cellulose.
- At least one salt selected from the group consisting of carbonates and bicarbonates At least one salt selected from the group consisting of carbonates and bicarbonates used in the foamable external skin preparation of the present invention (hereinafter referred to as “the following”) Can be used without particular limitation as long as it can be used in cosmetics, for example, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, calcium carbonate and the like, Among these, sodium hydrogen carbonate is particularly preferable from the viewpoint of foaming characteristics.
- the blending amount of at least one salt selected from the group consisting of carbonates and bicarbonates used in the foamable skin external preparation of the present invention is preferably 0.1 to 10 with respect to the total amount of foamable skin external preparation. It is 0.0% by mass, more preferably 0.5 to 5.0% by mass, and still more preferably 0.8 to 3.0% by mass. If the blending amount of at least one salt selected from the group consisting of carbonates and bicarbonates with respect to the total amount of the foamable external preparation for skin is less than 0.1% by mass, foaming with carbon dioxide gas tends to be insufficient. Moreover, since it will generate
- the amount of carbonate and the like contained in the foamable external preparation for skin (total amount) of the present invention is about 1.0 to 5,000 parts by mass with respect to 100 parts by mass of the hydrophobically modified alkyl cellulose.
- Water-soluble acid reacts with at least one salt selected from the group consisting of the carbonate and bicarbonate during use of the foamable external skin preparation of the present invention to form foam. It has the action of generating carbon dioxide, which is a gaseous component.
- water-soluble acid used in the foam-type external skin preparation of the present invention it is possible to use one that reacts with at least one salt selected from the group consisting of the carbonate and bicarbonate to generate carbon dioxide.
- water-soluble acids such as malic acid, succinic acid, succinic acid, maleic acid, citric acid, glycolic acid, mandelic acid, tartaric acid and glucono delta lactone (which becomes gluconic acid in aqueous solution) can be preferably exemplified
- Hydroxy acids such as citric acid, glycolic acid, mandelic acid, and tartaric acid, and glucono delta lactone (gluconic acid) are more preferable from the viewpoint of ease of incorporation when mixed in the final composition.
- a water-soluble acid can also contain only the said 1 type, and can also contain it in combination of 2 or more type.
- the blending amount of the water-soluble acid used in the foamable skin external preparation of the present invention is preferably 0.5 to 10.0% by mass, more preferably 1.0 to 5. 0% by mass. If the blending amount of the water-soluble acid with respect to the total amount of the foam-type skin external preparation is less than 0.5% by mass and exceeds 10.0% by mass, the pH of the foam-type skin external preparation cannot be adjusted well, and carbon dioxide is generated. Tend to be difficult.
- the amount of the water-soluble acid contained in the foamable external preparation for skin (total amount) of the present invention is about 5.0 to 5,000 parts by mass with respect to 100 parts by mass of the hydrophobically modified alkyl cellulose.
- polyhydric alcohol In the foamed skin external preparation of the present invention, it is preferable to further blend a polyhydric alcohol from the viewpoint of smoothing the physical properties of the foamed skin external preparation and the stability of the product.
- the polyhydric alcohol is, for example, a polyhydric alcohol having 2 to 6 carbon atoms and 2 to 3 oxygen atoms, specifically, ethylene glycol, diethylene glycol, propylene glycol, 1,3-propanediol, dipropylene glycol, 1 , 3-Butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 3-methyl-1,3-butanediol, glycerin, sorbitol, etc., among which easy availability and use Propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 1,2-pentanediol are particularly preferable from the viewpoint of adding feeling.
- the blending amount of the polyhydric alcohol is preferably 0.1 to 50.0% by mass with respect to the total amount of the foaming external preparation for skin. More preferred examples include a form containing 10.0 to 30.0% by mass.
- the blending amount of the polyhydric alcohol with respect to the total amount of the foam-type external preparation for skin is less than 0.1% by mass, the physical properties of the viscous composition become non-uniform (moromoro), making it difficult to mix and apply to the skin during use.
- it exceeds 50.0 mass% when using it, stickiness is strong and a feeling of use is not good.
- the blending amount of the polyhydric alcohol contained in the foamed external preparation for skin (total amount) of the present invention is about 1.0 to 50,000 parts by mass with respect to 100 parts by mass of the hydrophobically modified alkyl cellulose.
- the amount is preferably about 200 to 6,000 parts by mass.
- At least one salt and said water soluble acid is reacted is selected from the group consisting of the carbonates and bicarbonates, foam formation It has the action of generating carbon dioxide, which is a gaseous component. This carbon dioxide gas is held in a gel having a thickening effect composed of the hydrophobically modified alkyl cellulose and water.
- the amount of water used in the foamable skin external preparation of the present invention is preferably 30 to 99.3% by mass, more preferably 57 to 88.5 mass%, based on the total amount of the foamable external skin preparation. If the blending amount of water with respect to the total amount of the foam-type external preparation for skin is less than 30% by mass, the viscosity becomes too high to be mixed at the time of use, it is difficult to apply to the skin, and the production of the product itself is hindered. A trend is observed. On the other hand, if it exceeds 99.3% by mass, the effect of increasing the viscosity and maintaining carbon dioxide (bubbles) sufficiently in the final product tends to be low.
- the amount of water contained in the foamable external preparation for skin (total amount) of the present invention is preferably about 300 to 99,300 parts by mass with respect to 100 parts by mass of the hydrophobically modified alkylcellulose, About 140 to 17,700 parts by mass is more preferable.
- the foamable external preparation for skin of the present invention can contain optional components that are usually used in cosmetics.
- Optional ingredients include hydrocarbons such as squalane, liquid paraffin, petroleum jelly, liquid fats such as olive oil, macadamia nut oil, castor oil, solid fats such as coconut oil, palm oil, shea fat, waxes such as beeswax, carnauba wax, lanolin, etc.
- Higher alcohols such as stearyl alcohol, behenyl alcohol, isostearyl alcohol, synthetic ester oils such as cetyl octoate, isopropyl palmitate, glyceryl tri-2-ethylhexanoate, dimethylpolysiloxane, decamethylcyclopentasiloxane, silicone resin, Silicone oil such as amino-modified polysiloxane, glyceryl monostearate, propylene glycol monostearate, lipophilic nonionic surfactant such as sorbitan monostearate, decaglyceryl monostearate, P Hydrophilic nonionic surfactants such as E-glycerin monoisostearate, POE-sorbitan tetraoleate, POE-behenyl ether, coconut oil fatty acid monoethanolamide, sodium stearate, sodium N-stearoyl-L-glutamate, POE -Anionic surfactants such as sodium oleyl
- foam-type skin external preparation Even if the foam-type skin external preparation of the present invention is used as one agent, there is no problem in terms of physical properties.
- a form in which hydrophobic modified alkyl cellulose is contained in one agent, and at least one salt selected from the group consisting of hydrophobic modified alkyl cellulose, carbonate and bicarbonate in one agent hereinafter referred to as “carbonic acid”.
- carbonic acid a form containing a water-soluble acid, and a form containing a water-soluble acid and a polyhydric alcohol such as a hydrophobically modified alkyl cellulose and a carbonate in one agent.
- the water may be in a form contained in one agent, or in a form in which an appropriate amount is added at the time of use.
- Other optional components may be included.
- the foamable external preparation of the present invention is preferably a method (form) in which at least two agents, A agent containing carbonate and the like and B agent containing a water-soluble acid, are separated and mixed at the time of use.
- the hydrophobized modified alkyl cellulose is contained in the agent A and / or the agent B.
- water may be contained in the A agent and / or the B agent, or may be added as appropriate at any time when the A agent and the B agent are mixed at the time of use.
- the polyhydric alcohol and other optional components may be contained in the agent A and / or agent B.
- the water may be contained in any or all of the A agent, the B agent, and the C agent, or may be added as appropriate at the time of mixing the A agent, the B agent, and the C agent at the time of use.
- the polyhydric alcohol and other optional components may be contained in any or all of the A agent, the B agent, and the C agent.
- agent A containing at least one salt selected from the group consisting of carbonates and bicarbonates and agent B containing a water-soluble acid are separated and mixed at the time of use. It is preferable that At this time, the agent A containing at least one salt selected from the group consisting of carbonate and bicarbonate and the agent B containing a water-soluble acid are preferably liquid or granular (powdered) compositions.
- the conventional foam-type external skin preparation has excellent carbon dioxide foaming capacity and holding power that was not easily obtained, and from the skin. Good usability, such as prevention of dripping, can be achieved.
- the hydrophobized modified alkylcellulose is 0.1 to 10.0% by mass, carbonate and the like are 0.1 to 10.2. 0% by mass, 0.5 to 10.0% by mass of water-soluble acid, 0.1 to 50.0% by mass of polyhydric alcohol, and 30 to 99.3% by mass of water, It is preferable to mix and use each agent (additionally water) in an appropriate amount.
- the hydrophobized modified alkyl cellulose is contained in agent A and / or agent B.
- Water may be contained in the A agent or the B agent, and may be contained in the A agent and the B agent. Moreover, after mixing A agent and B agent, the form which adds water may be sufficient.
- the blending amount of the hydrophobically modified alkyl cellulose contained in the agent A and / or agent B is preferably 0.1 to 10.0% by mass, more preferably 0.5 to 0.5%, based on the total amount of the foamable external preparation for skin. It mix
- the blending amount of the hydrophobized modified alkyl cellulose with respect to the total amount of the foam-type external preparation for skin is less than 0.1% by mass, there is a tendency that the final product has a sufficient thickening effect and an effect on carbon dioxide (foam) retention.
- the content exceeds 10.0% by mass the viscosity becomes so high that it is difficult to mix at the time of use, it is difficult to apply to the skin, and the production of the product itself is hindered.
- the agent A when the agent A is a liquid composition containing 30 to 99.3% by mass of water, the content of the hydrophobized modified alkyl cellulose in the agent A is too high in viscosity and hardly comes out of the container. For the reason, it is preferably 0.1 to 10% by mass, more preferably 0.1 to 5.0% by mass.
- the agent A is a granular (powder) composition, the content of the hydrophobized modified alkyl cellulose in the agent A is too mixed after use and difficult to apply to the skin. Therefore, the content is preferably 1 to 40% by mass, more preferably 5 to 30% by mass.
- the content of the hydrophobized modified alkylcellulose in the agent B is too high in viscosity and difficult to come out of the container.
- the content is preferably 0.1 to 10% by mass, more preferably 0.1 to 5.0% by mass.
- the content of the hydrophobically modified alkyl cellulose in the B agent is too high to be mixed during use because the viscosity after blending becomes too high, and is difficult to apply to the skin. Therefore, the content is preferably 0.1 to 10% by mass, more preferably 0.1 to 5.0% by mass.
- the A agent and / or the B agent may be a liquid composition containing water.
- water is preferably 300 to 99,300 mass with respect to 100 parts by mass of the hydrophobized modified alkylcellulose contained in the total amount of the foamable external preparation for skin. Part, more preferably 1,140 to 17,700 parts by mass, is added at the time of use.
- the content of at least one salt (carbonate or the like) selected from the group consisting of carbonate and bicarbonate in the agent A is 0.1 to 0.1% relative to the total amount of the foamable external skin preparation such as the final product.
- the amount is preferably 10.0% by mass, and more preferably 0.5 to 5.0% by mass.
- foaming due to carbon dioxide gas at the time of use is not sufficiently obtained, and when it exceeds 10.0% by mass, a large amount of carbon dioxide gas is generated. There are concerns such as irritation to the skin.
- the agent A is a liquid or granular or powdery composition, it is sufficient that the carbonate in the above range is included.
- the content of the water-soluble acid in the agent B is preferably 1.0 to 80.0% by mass. It is preferable that the content of the water-soluble acid in the agent B is 0.5 to 10.0% by mass with respect to the total amount of the foam-type external skin preparation such as the final product. Further, it is particularly preferable that the blending amount is such that the pH of the foam-type external preparation for skin after mixing with the agent A is 3.0 to 8.0. If the pH is less than 3.0, there is a concern that irritation may occur on the skin when used, and if the pH exceeds 8.0, the decomposition of carbonate is extremely gentle, so the amount of carbon dioxide generated is insufficient. Is mentioned.
- the content of the water-soluble acid in the agent B is difficult to adjust to the pH described in the present application when the amount is less than 1.0% by mass and more than 80.0% by mass.
- B agent is a liquid or a granular or powdery composition, the water-soluble acid of the said range should just be contained.
- foamed skin external preparation of the present invention is used as two agents, A and B, there is no problem in terms of physical properties even if the polyhydric alcohol is contained in the A and / or B agents.
- the blending amount of the polyhydric alcohol contained in the agent A and / or agent B is preferably 0.1 to 50.0% by mass, more preferably 10.0 to 30.%, based on the total amount of the foaming external preparation for skin. It mix
- the blending amount of the polyhydric alcohol with respect to the total amount of the foam-type external preparation for skin is less than 0.1% by mass, the physical properties of the viscous composition become non-uniform (moromoro), making it difficult to mix and apply to the skin during use. Moreover, when it exceeds 50.0 mass%, when using it, stickiness is strong and a feeling of use is not good.
- the hydrophobized modified alkylcellulose is 0.1 to 10.0% by mass, carbonate and the like are 0.1 to 10.2. 0% by mass, 0.5 to 10.0% by mass of water-soluble acid, 0.1 to 50.0% by mass of polyhydric alcohol, and 30 to 99.3% by mass of water, It is preferable to mix and use A agent and B agent (additionally water) in an appropriate amount.
- the agent A is a liquid composition containing 30 to 99.3% by mass of water
- the content of the carbonate and the like in the agent A can sufficiently obtain foaming by carbon dioxide gas at the time of use.
- the amount is preferably 0.1 to 10.0% by mass, more preferably 0.5 to 5.0% by mass, because carbon dioxide gas can be prevented and irritation can be reduced when used.
- the agent A is a granular (powder) composition
- the content of carbonate and the like in the agent A is preferably 0.00 with respect to the total amount of the foamable external preparation for the final product or the like for the same reason.
- the content may be adjusted to 1 to 10.0% by mass, more preferably 0.5 to 5.0% by mass.
- the content of the water-soluble acid in the agent B is preferably 0.5 to 10.0% by mass.
- the content of the water-soluble acid in the agent B is preferably 0.5 to 50% by mass.
- the water-soluble acid is preferably contained in an amount of 0.1 to 10.0% by mass with respect to the total amount of the foam-type external skin preparation such as the final product after mixing with the agent A and the agent C described later. It is particularly preferable that the amount of the external preparation for skin is 3.0 to 8.0.
- the pH is less than 3.0, there is a concern that irritation may occur on the skin when used, and if the pH exceeds 8.0, the decomposition of carbonate is extremely gentle, so the amount of carbon dioxide generated is insufficient. Is mentioned. Further, the content of the water-soluble acid in the agent B tends to be difficult to adjust to the pH described in the present application if the addition amount is out of the content.
- the content of the hydrophobically modified alkyl cellulose in the agent C is preferably 0.1 to 10.0% by mass, more preferably 0.5 to 5.0% by mass.
- the content of the hydrophobically modified alkyl cellulose in the agent C is preferably 0.1 to 10.0% by mass, more preferably 0.5 to 5. 0% by mass.
- the hydrophobized modified alkyl cellulose may be adjusted to 0.1 to 10.0% by mass with respect to the total amount of the foam-type external skin preparation such as the final product.
- the blending amount of the hydrophobized modified alkyl cellulose within the above range, it is possible to obtain a sufficient thickening effect and carbon dioxide (foam) retention effect in the final product, and the viscosity does not become too high and is easy to mix during use. Moreover, it is easy to apply to the skin and is preferable for the production of the product itself.
- the polyhydric alcohol may be included in any of the A agent, the B agent and the C agent. Even if it is included, there is no problem in terms of physical properties.
- the blending amount of the polyhydric alcohol is preferably 0.1 to 50.0% by mass, more preferably 10.0 to 30.0% by mass with respect to the total amount of the foam-type external skin preparation, It mix
- the physical properties of the viscous composition in the final product can be kept uniform (not lingering), making it suitable for mixing work and application to the skin. It can be performed and there is no stickiness at the time of use, and the usability can be improved.
- the water is preferably 1.0 with respect to 100 parts by mass of the hydrophobized modified alkylcellulose contained in the total amount of the foamed external preparation for skin. It is added at the time of use so that it is contained at 50,000 parts by mass, more preferably 200-6,000 parts by mass.
- the hydrophobized modified alkylcellulose is 0.1 to 10.0% by mass, carbonate and the like are 0.1 to 10.2.
- foam-type skin external preparations Preferred specific examples of the foam-type skin external preparation of the present invention are shown below as A agent containing carbonate and B agent containing water-soluble acid.
- A Hydrophobized modified alkyl cellulose in which the A agent is a liquid composition and the B agent is a granular (powder) composition is included in the A agent and / or the B agent.
- a preferable mixing ratio (mass ratio) of the A agent and the B agent may be appropriately adjusted based on the blending amount of each component contained in the A agent and the B agent, and is not particularly limited, but is usually 30: It is preferable to use a mixing ratio of 0.1 to 10. For example, it is more preferable to use the mixing ratio of agent A: agent B at a mixing ratio of 30: 1, 30: 3, 30: 5, 30: 7, or the like.
- Sangelose 60L when blended with B agent
- B agent 0.1 to 10.0% by mass (more preferably 0.5 to 3% by mass)
- Water-soluble acid for example, citric acid, glycolic acid, malic acid, succinic acid, etc.
- Excipients for example, maltitol, lactose, gluconolactone, etc. 20.0-80.0% by mass Agent A and Agent B are mixed immediately before use.
- the preferable mixing ratio (mass ratio) of the A agent and the B agent is not particularly limited, but it is usually preferable to use a mixing ratio of 30: 1 to 45.
- the mixing ratio of agent A: agent B may be used at a mixing ratio of 1: 1.
- agent A Hydrophobized modified alkyl cellulose in which agent A is a granular (powder) composition and agent B is a liquid composition is included in agent A and / or agent B.
- [A agent] Hydrophobized modified alkyl cellulose (as an example, Daido Kasei Kogyo Co., Ltd. trade name: Sangelose 60L) (when blended with agent A) 0.1-30% by mass (more preferably 20-30% by mass) -At least one salt selected from the group consisting of carbonates and bicarbonates (for example, sodium bicarbonate, sodium carbonate, etc.) 50 to 90% by mass (more preferably 65 to 80% by mass) ⁇ Polyhydric alcohol (for example, 1,3-butylene glycol, 1,2-pentanediol, or other components) 0.1 to 50.0% by mass [B agent] Water 40.0-90.0% by mass (more preferably 40-80% by mass) Hydrophobized modified alkyl cellulose (as an example, Daido Kasei Kogyo Co., Ltd.
- Sangelose 60L when blended with B agent
- B agent 0.1 to 10.0% by mass (more preferably 0.5 to 3% by mass)
- Water-soluble acid for example, citric acid, glycolic acid, malic acid, succinic acid, etc.
- Excipients for example, maltitol, lactose, gluconolactone, etc. 20.0-80.0% by mass Agent A and Agent B are mixed immediately before use.
- the preferable mixing ratio (mass ratio) of the agent A and the agent B is not particularly limited, but it is usually preferable to use the mixing ratio of 1: 2 to 300.
- the foam-type external skin preparation shown in the present invention mainly refers to a skin care preparation represented by a cosmetic pack, but can also be used as a clinical therapeutic preparation.
- the method of promoting the circulation of the whole body (scalp), the method of vasodilation of the whole body (scalp), etc. using the foamed external preparation for skin of the present invention is preferable.
- Example 1 The foam type pack A agent and B agent shown below (Table 1: Prescription) were prepared. About the obtained foaming type
- stearoxy hydroxypropyl methylcellulose trade name manufactured by Daido Kasei Kogyo Co., Ltd .: Sangelose 60L
- carboxymethyl cellulose trade name of Daicel Finechem Co., Ltd .: CMC Daicel 1380, sodium alginate: Food Co., Ltd.
- Sodium bicarbonate Product name of Tosoh Corporation: Sodium bicarbonate (Pharmacopoeia ), Phenoxyethanol: High-solve EPH from Toho Chemical Industry Co., Ltd.
- Citric acid Trade name of Iwata Chemical Industry Co., Ltd .: Citric acid (crystal) and Maltitol: Trade name of Hayashibara Biochemical Laboratories Co., Ltd .: Powder Mabit Was used.
- Example 1 was excellent in foaming and foam retention at the time of mixing, and did not sag from the cheeks during use due to the elasticity of the foam.
- Comparative Example 1 and Comparative Example 2 were insufficient in foaming and foam retention, and drew from the cheeks during use.
- Example 2 The high-viscosity foam-type pack A agent and B agent that do not cause dripping as shown below (Table 3: prescription) were prepared. About the obtained foaming type
- 1,2-pentanediol trade name: Diol PD of Higher Alcohol Industry Co., Ltd. was used.
- Example 2 was excellent in foaming and foam retention during mixing. In addition, it was sufficiently viscous during use and did not sag from the cheek. On the other hand, in Comparative Example 3, although the liquid did not sag from the cheeks when used, both foam foaming and foam retention during mixing were insufficient.
- Example 3 The high-viscosity foam-type pack A agent and B agent that did not cause dripping as shown below (Table 5: Formulation) were prepared (Examples 3-1 to 3-5). This formulation contains water and stearoxyhydroxypropylmethylcellulose in agent A (agent containing carbonate or the like). About the obtained foaming type pack, these were mixed in the ratio of A agent (30g) and B agent (5.0g), and confirmation of foaming at the time of mixing and foam retention power were evaluated. In addition, the presence or absence of dripping from the cheek when actually used on the cheek was also evaluated.
- sodium carbonate trade name of Tosoh Corporation: sodium carbonate
- dipotassium glycyrrhizinate trade name of Maruzen Pharmaceutical Co., Ltd .: glycyritin K2
- tetrasodium edetate trade name of Nagase ChemteX Corporation: Clewat T
- Malic acid Trade name of Fuso Chemical Industry: Fuso malate
- Succinic acid Trade name of Fuso Chemical Industry: Succinic acid
- glucono delta lactone Trade name of Riken Vitamin Co., Ltd.
- Likenlactone was used.
- Examples 3-1 to 3 to 5 were excellent in foaming and foam retention during mixing as in Example 1. In addition, it was sufficiently viscous during use and did not sag from the cheek.
- Example 4 The high-viscosity foam-type pack A agent and B agent shown in the following (Table 6: prescription) were prepared (Examples 4-1 to 4-5).
- This prescription contains stearoxyhydroxypropylmethylcellulose in agent A (agent containing carbonate or the like) and agent B (agent containing a water-soluble acid), and water in agent B.
- agent A agent containing carbonate or the like
- agent B agent containing a water-soluble acid
- water in agent B About the obtained foaming type
- glycerin trade name of Sakamoto Yakuhin Kogyo Co., Ltd .: concentrated glycerin for cosmetics
- xanthan gum trade name of Sanki Co., Ltd .: Celtrol, methyl paraoxybenzoate: Ueno Pharmaceutical Co., Ltd .: platinth M Using.
- Examples 4-1 to 4-5 were excellent in foaming and foam retention during mixing as in Example 1. In addition, it was sufficiently viscous during use and did not sag from the cheek.
- Example 5 The high-viscosity foam-type pack A agent and B agent shown in the following (Table 7: prescription) were prepared (Examples 5-1 to 5-5).
- This formulation includes stearoxyhydroxypropylmethylcellulose and water in agent A (agent containing carbonate and the like) and agent B (agent containing a water-soluble acid), respectively.
- agent A agent containing carbonate and the like
- agent B agent containing a water-soluble acid
- Examples 5-1 to 5-5 were excellent in foaming and foam retention during mixing as in Example 2. In addition, it was sufficiently viscous during use and did not sag from the cheek.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
項1.疎水化変性アルキルセルロースを必須成分とする発泡型皮膚外用剤。
項2.疎水化変性アルキルセルロース;炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩;並びに水溶性酸を含む、前記項1に記載の発泡型皮膚外用剤。
項3.前記疎水化変性アルキルセルロースが、
下記構造式(1):
基:-[CH2CH2-k(CH3)kO]mH、
又は、基:-CH2CH(OH)CH2OCjH2j+1である。
nは100~10000の整数、kは0又は1の整数、mは1~10の整数、
jは6~26の整数を示す。]
で表されるものであって、
該疎水化変性アルキルセルロースが、基:-CH2CH(OH)CH2OCjH2j+1を必ず含むものである、
前記項1又は2に記載の発泡型皮膚外用剤。
項4.前記構造式(1)で表される疎水化変性アルキルセルロースが、
低級アルキル基:10.0~50.0質量%、
基:-[CH2CH2-k(CH3)kO]mH:3.0~20.0質量%、及び
基:-CH2CH(OH)CH2OCjH2j+1:0.1~10.0質量%
を含む前記項3に記載の発泡型皮膚外用剤。
項5.前記構造式(1)式に含まれる前記基:-CH2CH(OH)CH2OCjH2j+1のjの値が18である前記項3又は4に記載の発泡型皮膚外用剤。
項6.前記炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩が、炭酸水素ナトリウムであることを特徴とする前記項2~5のいずれかに記載の発泡型皮膚外用剤。
項7.前記水溶性酸が、ヒドロキシ酸であることを特徴とする前記項2~6のいずれかに記載の発泡型皮膚外用剤。
項8.前記ヒドロキシ酸が、クエン酸であることを特徴とする前記項7に記載の発泡型皮膚外用剤。
項9.前記発泡型皮膚外用剤が、更に、多価アルコールを含む前記項1~8のいずれかに記載の発泡型皮膚外用剤。
項10.前記多価アルコールが、プロピレングリコール、ジプロピレングリコール、1,3‐ブチレングリコール、1,2‐ペンタンジオールからなる群から選択される1種又は2種以上を含んでなることを特徴とする前記項9に記載の発泡型皮膚外用剤。
項11.発泡型皮膚外用剤が、炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩を含むA剤と、水溶性酸を含むB剤が、分離されており、使用時に混合されるものである、ことを特徴とする前記項2~10のいずれかに記載の発泡型皮膚外用剤。
本発明の発泡型皮膚外用剤に用いられる疎水化変性アルキルセルロースは、セルロースエーテル誘導体に、疎水性基である長鎖アルキル基を導入したものである。
基:-[CH2CH2-k(CH3)kO]mH、
又は、基:-CH2CH(OH)CH2OCjH2j+1である。
nは100~10000の整数、kは0又は1の整数、mは1~10の整数、
jは6~26の整数を示す。]
で表されるものであって、
該疎水化変性アルキルセルロースが、基:-CH2CH(OH)CH2OCjH2j+1を必ず含むものであることが好ましい。
本発明の発泡型皮膚外用剤に用いられる炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩(以下、「炭酸塩等」とも記す)は、化粧料で使用できるものであれば特段の限定無く使用でき、例えば、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸水素カリウム、炭酸カルシウムなどが例示でき、これらの中では、発泡特性の面から炭酸水素ナトリウムが特に好ましい。
水溶性酸は、本発明の発泡型皮膚外用剤の使用時において、前記炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩と反応して、泡沫形成の気体成分である炭酸ガスを発生させる作用を有する。
本発明の発泡型皮膚外用剤では、発泡型皮膚外用剤の物性を滑らかにする目的や製品の安定性の点から、更に多価アルコールを配合することが好ましい。
本発明の発泡型皮膚外用剤では、使用時において、前記炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩と前記水溶性酸とが反応して、泡沫形成の気体成分である炭酸ガスを発生させる作用を有する。この炭酸ガスが、前記疎水化変性アルキルセルロース及び水からなる増粘効果を有するゲルに保持される。
また、本発明の発泡型皮膚外用剤には、上記必須成分以外に通常化粧料で使用される任意成分を含有することができる。任意成分としては、スクワラン、流動パラフィン、ワセリン等の炭化水素、オリーブ油、マカデミアナッツ油、ヒマシ油、等の液体油脂、ヤシ油、パーム油、シア脂等の固体油脂、ミツロウ、カルナウバロウ、ラノリン等のロウ類、ステアリルアルコール、ベヘニルアルコール、イソステアリルアルコール等の高級アルコール、オクタン酸セチル、パルミチン酸イソプロピル、トリ-2-エチルヘキサン酸グリセリル等の合成エステル油、ジメチルポリシロキサン、デカメチルシクロペンタシロキサン、シリコーン樹脂、アミノ変性ポリシロキサン等のシリコーン油、モノステアリン酸グリセリン、モノステアリン酸プロピレングリコール、ソルビタンモノステアレート等の親油性非イオン界面活性剤、モノステアリン酸デカグリセリル、POE-グリセリンモノイソステアレート、POE-ソルビタンテトラオレエート、POE-ベヘニルエーテル、ヤシ油脂肪酸モノエタノールアミド等の親水性非イオン界面活性剤、ステアリン酸ナトリウム、N-ステアロイル-L-グルタミン酸ナトリウム、POE-オレイルエーテルリン酸ナトリウム、ラウロイルサルコシンナトリウム、ラウロイルメチルアラニンナトリウム等の陰イオン界面活性剤、塩化ステアリルトリメチルアンモニウム、ステアリン酸ジメチルアミノプロピルアミド、塩化ベンザルコニウム等の陽イオン界面活性剤、ヤシ油脂肪酸アミドプロピルベタイン、ラウリルジメチルアミノ酢酸ベタイン等の両性界面活性剤、エタノール、イソプロパノール等の低級アルコール、キサンタンガム、ヒドロキシエチルセルロース、カルボキシビニルポリマー等の水溶性高分子、エデト酸二ナトリウム等の金属イオン封鎖剤、その他に粉末成分、紫外線吸収剤、酸化防止剤、pH調整剤、有機アミン、防腐剤(フェノキシエタノール、グリセリンエチルヘキシルエーテル、メチルパラベン等)、殺菌剤、消炎剤、収れん剤、美白剤、ビタミン類、アミノ酸、血行促進剤、賦活剤、賦形剤(マルチトール、乳糖、デキストリン、デンプン等)、清涼剤、各種抽出物、香料、水等が挙げられる。しかしながら、本発明はもちろんこれらの例に限定されるものではない。
本発明の発泡型皮膚外用剤は、1剤として使用しても物性面では何ら問題はない。例えば、1剤の中に疎水化変性アルキルセルロースが含まれる形態、1剤の中に疎水化変性アルキルセルロース、炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩(以下、「炭酸塩等」とも記す)、並びに水溶性酸を含む形態、1剤の中に疎水化変性アルキルセルロース、炭酸塩等、水溶性酸、並びに多価アルコールを含む形態等がある。このとき、水は、1剤の中に含まれる形態でも良く、使用時に適量を添加する形態でも良い。その他の前記任意成分を含んでも良い。
2剤(炭酸塩等を含むA剤及び水溶性酸を含むB剤)として使用する場合の本発明の発泡型皮膚外用剤を説明する。
3剤(炭酸塩等を含むA剤、水溶性酸を含むB剤及び疎水化変性アルキルセルロースを含むC剤)として使用する場合の本発明の発泡型皮膚外用を説明する。水はA剤、B剤及びC剤のいずれかに含まれていても良く、全てに含まれていても良い。また、A剤、B剤及びC剤を混合した後に、水を添加する形態であっても良い。
以下に炭酸塩等を含むA剤及び水溶性酸を含むB剤とする本発明の泡型皮膚外用剤の好ましい具体例を示す。
疎水化変性アルキルセルロースは、A剤及び/又はB剤に含まれる。
・水 40.0~90.0質量%(更に好ましくは70~85質量%)
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(A剤に配合する場合)
0.1~10.0質量%(更に好ましくは0.5~3質量%)
・炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩(一例として、炭酸水素ナトリウム、炭酸ナトリウム等)
0.1~5.0質量%(更に好ましくは0.5~4質量%)
・多価アルコール(一例として、1,3‐ブチレングリコール、1,2‐ペンタンジオール等、またはその他成分)
0.1~50.0質量%(更に好ましくは10~30質量%)
[B剤]
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(B剤に配合する場合)
0.1~10.0質量%(更に好ましくは0.5~3質量%)
・水溶性酸(一例として、クエン酸、グリコール酸、リンゴ酸、コハク酸等)
20.0~80.0質量%(更に好ましくは25~55質量%)
・賦形剤(一例として、マルチトール、乳糖、グルコノラクトン等)
20.0~80.0質量%
A剤とB剤とを使用直前に混合する。
疎水化変性アルキルセルロースは、A剤及び/又はB剤に含まれる。
・水 40.0~90.0質量%(更に好ましくは70~85質量%)
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(A剤に配合する場合)
0.1~10.0質量%(更に好ましくは0.5~3質量%)
・炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩(一例として、炭酸水素ナトリウム、炭酸ナトリウム等)
0.1~10.0質量%(更に好ましくは0.5~5.0質量%)
・多価アルコール(一例として、1,3‐ブチレングリコール、1,2‐ペンタンジオール等、またはその他成分)
0.1~50.0質量%(更に好ましくは10~30質量%)
[B剤]
・水 40.0~90.0質量%(更に好ましくは40~80質量%)
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(B剤に配合する場合)
0.1~10.0質量%(更に好ましくは0.5~3質量%)
・水溶性酸(一例として、クエン酸、グリコール酸、リンゴ酸、コハク酸等)
1~80.0質量%(更に好ましくは1.5~60質量%)
・賦形剤(一例として、マルチトール、乳糖、グルコノラクトン等)
20.0~80.0質量%
A剤とB剤とを使用直前に混合する。
疎水化変性アルキルセルロースは、A剤及び/又はB剤に含まれる。
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(A剤に配合する場合)
0.1~30質量%(更に好ましくは20~30質量%)
・炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩(一例として、炭酸水素ナトリウム、炭酸ナトリウム等)
50~90質量%(更に好ましくは65~80質量%)
・多価アルコール(一例として、1,3‐ブチレングリコール、1,2‐ペンタンジオール等、またはその他成分)
0.1~50.0質量%
[B剤]
・水 40.0~90.0質量%(更に好ましくは40~80質量%)
・疎水化変性アルキルセルロース(一例として、大同化成工業(株)商品名:サンジェロース60L)(B剤に配合する場合)
0.1~10.0質量%(更に好ましくは0.5~3質量%)
・水溶性酸(一例として、クエン酸、グリコール酸、リンゴ酸、コハク酸等)
1~80.0質量%(更に好ましくは1.5~60質量%)
・賦形剤(一例として、マルチトール、乳糖、グルコノラクトン等)
20.0~80.0質量%
A剤とB剤とを使用直前に混合する。
下記(表1:処方)に示す発泡型パックA剤およびB剤を調製した。得られた発泡型パックについて、これらをA剤(30g)、B剤(1.0g)の割合で混合し、混合時の発泡の確認・泡保持力について評価した。また、実際に頬部に使用した時の頬からの液垂れの有無についても合わせて評価した。評価結果を下記(表2:結果)に示す。評価は目視にて行い、下記の項目にて判定した。
○:有意に発泡を確認できた。
△:混合開始は確認できたが、混合中に泡の大気中への放出による減少が確認された。
×:混合開始は確認できたが、混合中に泡の大部分が大気中へ放出してしまった。
○:初期状態(混合直後)から変化なし(泡が抜けていない)。
△:初期状態から若干の減少は見られるが、十分な泡の残存が確認できる。
×:あきらかに泡の減少が確認できる。
○:液垂れは起こらなかった。
△:時間が経つと液垂れが起きた。
×:塗布直後から液垂れが起きた。
下記(表3:処方)に示す液垂れを起こさないような高粘度の発泡型パックA剤およびB剤を調製した。得られた発泡型パックについて、これらをA剤(30g)、B剤(1.0g)の割合で混合し、混合時の発泡の確認・泡保持力について評価した。また、実際に頬部に使用した時の頬からの液垂れの有無についても合わせて評価した。評価結果を下記(表4:結果)に示す。評価は目視にて行い、下記の項目にて判定した。
○:有意に発泡を確認できた。
△:発泡は確認できたが、その反応は穏やかで、混合中に大気中への放出がみられた。
×:混合開始は確認できたが、混合中に泡の大部分が大気中へ放出してしまった。
○:初期状態(混合直後)から変化なし(泡が抜けていない)。
△:初期状態から若干の減少は見られるが、十分な泡の残存が確認できる。
×:あきらかに泡の減少が確認できる。
○:液垂れは起こらなかった。
△:時間が経つと液垂れが起きた。
×:塗布直後から液垂れが起きた。
下記(表5:処方)に示す液垂れを起こさないような高粘度の発泡型パックA剤およびB剤を調製した(実施例3-1~3-5)。この処方は、A剤(炭酸塩等を含む剤)に水及びステアロキシヒドロキシプロピルメチルセルロースを含むものである。得られた発泡型パックについて、これらをA剤(30g)、B剤(5.0g)の割合で混合し、混合時の発泡の確認・泡保持力について評価した。また、実際に頬部に使用した時の頬からの液垂れの有無についても合わせて評価した。
下記(表6:処方)に示す液垂れを起こさないような高粘度の発泡型パックA剤およびB剤を調製した(実施例4-1~4-5)。この処方は、A剤(炭酸塩等を含む剤)及びB剤(水溶性酸を含む剤)にステアロキシヒドロキシプロピルメチルセルロースを含み、B剤に水を含むものである。得られた発泡型パックについて、これらをA剤(2.0g)、B剤(20.0g)の割合で混合し、混合時の発泡の確認・泡保持力について評価した。また、実際に頬部に使用した時の頬からの液垂れの有無についても合わせて評価した。
下記(表7:処方)に示す液垂れを起こさないような高粘度の発泡型パックA剤およびB剤を調製した(実施例5-1~5-5)。この処方は、A剤(炭酸塩等を含む剤)及びB剤(水溶性酸を含む剤)に、夫々ステアロキシヒドロキシプロピルメチルセルロース及び水を含むものである。得られた発泡型パックについて、これらをA剤(10.0g)、B剤(10.0g)の割合で混合し、混合時の発泡の確認・泡保持力について評価した。また、実際に頬部に使用した時の頬からの液垂れの有無についても合わせて評価した。
Claims (11)
- 疎水化変性アルキルセルロースを必須成分とする発泡型皮膚外用剤。
- 疎水化変性アルキルセルロース;炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩;並びに水溶性酸を含む、請求項1に記載の発泡型皮膚外用剤。
- 前記構造式(1)で表される疎水化変性アルキルセルロースが、
低級アルキル基:10.0~50.0質量%、
基:-[CH2CH2-k(CH3)kO]mH:3.0~20.0質量%、及び
基:-CH2CH(OH)CH2OCjH2j+1:0.1~10.0質量%
を含む請求項3に記載の発泡型皮膚外用剤。 - 前記構造式(1)式に含まれる前記基:-CH2CH(OH)CH2OCjH2j+1のjの値が18である請求項3又は4に記載の発泡型皮膚外用剤。
- 前記炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩が、炭酸水素ナトリウムであることを特徴とする請求項2~5のいずれかに記載の発泡型皮膚外用剤。
- 前記水溶性酸が、ヒドロキシ酸であることを特徴とする請求項2~6のいずれかに記載の発泡型皮膚外用剤。
- 前記ヒドロキシ酸が、クエン酸であることを特徴とする請求項7に記載の発泡型皮膚外用剤。
- 前記発泡型皮膚外用剤が、更に、多価アルコールを含む請求項1~8のいずれかに記載の発泡型皮膚外用剤。
- 前記多価アルコールが、プロピレングリコール、ジプロピレングリコール、1,3‐ブチレングリコール、1,2‐ペンタンジオールからなる群から選択される1種又は2種以上を含んでなることを特徴とする請求項9に記載の発泡型皮膚外用剤。
- 発泡型皮膚外用剤が、炭酸塩及び重炭酸塩からなる群から選ばれる少なくとも1種の塩を含むA剤と、水溶性酸を含むB剤が、分離されており、使用時に混合されるものである、ことを特徴とする請求項2~10のいずれかに記載の発泡型皮膚外用剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137010489A KR101729100B1 (ko) | 2010-09-24 | 2011-09-22 | 발포형 피부 외용제 |
JP2012501073A JP5039243B2 (ja) | 2010-09-24 | 2011-09-22 | 発泡型皮膚外用剤 |
CN201180045432.9A CN103118660B (zh) | 2010-09-24 | 2011-09-22 | 发泡型皮肤外用剂 |
US13/825,404 US20130244976A1 (en) | 2010-09-24 | 2011-09-22 | Foam-type external skin preparation |
EP11798298.3A EP2620138B1 (en) | 2010-09-24 | 2011-09-22 | Foam-type external skin preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010213344 | 2010-09-24 | ||
JP2010-213344 | 2010-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011162421A2 true WO2011162421A2 (ja) | 2011-12-29 |
WO2011162421A3 WO2011162421A3 (ja) | 2012-03-08 |
Family
ID=45371895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/071734 WO2011162421A2 (ja) | 2010-09-24 | 2011-09-22 | 発泡型皮膚外用剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20130244976A1 (ja) |
EP (1) | EP2620138B1 (ja) |
JP (3) | JP5039243B2 (ja) |
KR (1) | KR101729100B1 (ja) |
CN (1) | CN103118660B (ja) |
WO (1) | WO2011162421A2 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013170152A (ja) * | 2012-02-22 | 2013-09-02 | Toyo Aerosol Ind Co Ltd | 泡沫形成エアゾール組成物 |
WO2013129414A1 (ja) * | 2012-02-29 | 2013-09-06 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素を発生する美容シート製品 |
WO2013129413A1 (ja) * | 2012-02-29 | 2013-09-06 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素含有組成物の調製用キット |
WO2013157034A1 (ja) * | 2012-04-17 | 2013-10-24 | コスメティック・ティエルナ有限会社 | 皮膚外用剤調製用組成物 |
JP2015034132A (ja) * | 2013-08-07 | 2015-02-19 | 大同化成工業株式会社 | 外用剤用組成物 |
JP5692618B1 (ja) * | 2014-05-12 | 2015-04-01 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2015151371A (ja) * | 2014-02-14 | 2015-08-24 | ロレアル | 二酸化炭素を生成し、保持するキット |
JP2015157793A (ja) * | 2014-02-24 | 2015-09-03 | 株式会社ピカソ美化学研究所 | 二酸化炭素発生組成物 |
JP2015214534A (ja) * | 2015-01-21 | 2015-12-03 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2016000712A (ja) * | 2014-05-22 | 2016-01-07 | 株式会社アイビーティジェイ | 二酸化炭素外用剤調製用組成物、その製造方法及び評価方法、並びに二酸化炭素外用剤 |
JP2016008181A (ja) * | 2014-06-23 | 2016-01-18 | 株式会社東洋新薬 | 皮膚外用剤用キット |
US20160067155A1 (en) * | 2014-09-10 | 2016-03-10 | Tadahiro Shimada | Foamable cosmetic product |
JP2018162289A (ja) * | 2018-06-25 | 2018-10-18 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2018199731A (ja) * | 2018-09-27 | 2018-12-20 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2020037587A (ja) * | 2019-11-18 | 2020-03-12 | 株式会社東洋新薬 | 皮膚外用剤用キット |
WO2024141771A1 (en) | 2022-12-30 | 2024-07-04 | L V M H Recherche | Oil-in-water emulsion |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130244976A1 (en) * | 2010-09-24 | 2013-09-19 | Daido Chemical Corporation | Foam-type external skin preparation |
JP5564130B1 (ja) * | 2013-03-18 | 2014-07-30 | 株式会社みやびコスメティックス | 発泡型皮膚外用剤 |
JP2015007017A (ja) * | 2013-06-26 | 2015-01-15 | 株式会社東洋新薬 | 発泡性皮膚外用剤 |
JP5648878B2 (ja) * | 2013-07-23 | 2015-01-07 | 株式会社ピカソ美化学研究所 | 二剤式二酸化炭素発生組成物 |
JP2015010089A (ja) * | 2014-02-06 | 2015-01-19 | 株式会社東洋新薬 | 発泡性皮膚外用剤 |
BR112016022293A2 (pt) | 2014-03-28 | 2017-08-15 | Galderma Res & Dev | Composição que contém peróxido de benzoíla, uso cosmético de uma composição, medicamento destinado a uma aplicação tópica sobre a pele, kit e processo de preparação de uma composição autoespumante |
KR101426914B1 (ko) | 2014-04-25 | 2014-08-05 | 주식회사 뉴앤뉴 | 두피 마사지 조성물 세트 |
CN107613955B (zh) | 2015-04-22 | 2023-11-17 | 汉高股份有限及两合公司 | 可发泡的个人护理组合物及其用途 |
FR3041539B1 (fr) * | 2015-09-29 | 2018-10-26 | Galderma Research & Development | Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis. |
FR3041538B1 (fr) | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis. |
FR3041536B1 (fr) | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne. |
FR3041540B1 (fr) * | 2015-09-29 | 2018-10-26 | Galderma Research & Development | Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine. |
FR3041535B1 (fr) | 2015-09-29 | 2019-01-25 | Galderma Research & Development | Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose. |
FR3041541B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee comprenant de l'ivermectine |
FR3041537B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee. |
JP6987374B2 (ja) * | 2016-03-31 | 2021-12-22 | 株式会社東洋新薬 | 発泡性皮膚外用剤 |
JP7070880B2 (ja) * | 2016-09-30 | 2022-05-18 | 株式会社東洋新薬 | 発泡性皮膚外用剤用キット |
DE102017213331A1 (de) * | 2017-08-02 | 2019-02-07 | Beiersdorf Ag | Kosmetikum zur Gesichtsreinigung |
CN109568153B (zh) | 2017-09-29 | 2024-05-24 | 株式会社资生堂 | 水包油型乳化组合物及其制备方法和制品 |
US11253111B2 (en) | 2019-08-22 | 2022-02-22 | Gpcp Ip Holdings Llc | Skin care product dispensers and associated self-foaming compositions |
CN118029165A (zh) * | 2024-04-12 | 2024-05-14 | 四川大学 | 改性羊毛纤维、制备方法、复合发泡材料及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60215606A (ja) | 1984-04-12 | 1985-10-29 | Kao Corp | パツク剤 |
JP2004238333A (ja) | 2003-02-06 | 2004-08-26 | Hiromaito Co Ltd | 炭酸ガス経皮吸収用シート状物及びフェースパック |
JP4248878B2 (ja) | 2001-04-06 | 2009-04-02 | ネオケミア株式会社 | 二酸化炭素外用剤調製用組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228277A (en) * | 1979-02-12 | 1980-10-14 | Hercules Incorporated | Modified nonionic cellulose ethers |
JP2610052B2 (ja) * | 1989-11-07 | 1997-05-14 | 信越化学工業株式会社 | 外用ゲル基剤 |
JPH03161415A (ja) * | 1989-11-21 | 1991-07-11 | Kao Corp | 薬用化粧料 |
JP3180111B2 (ja) * | 1995-08-10 | 2001-06-25 | 花王株式会社 | 新規多糖誘導体 |
JPH0987130A (ja) * | 1995-09-21 | 1997-03-31 | Shiseido Co Ltd | 乳化組成物 |
JP4659980B2 (ja) * | 1997-11-07 | 2011-03-30 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素含有粘性組成物 |
JP2000319187A (ja) * | 1999-05-06 | 2000-11-21 | Medion Research Laboratories Inc | 二酸化炭素経皮・経粘膜吸収用組成物 |
CN101119703A (zh) * | 2004-12-16 | 2008-02-06 | 赫尔克里士公司 | 疏水改性的多糖的个人护理和家用组合物 |
JPWO2007066497A1 (ja) * | 2005-12-09 | 2009-05-14 | ライオン株式会社 | 歯磨組成物 |
US20070148112A1 (en) | 2005-12-28 | 2007-06-28 | Avon Products, Inc. | Foaming, color-changing topical composition and method of imparting a cosmetic effect |
EP2228052A1 (en) * | 2009-03-09 | 2010-09-15 | Coty Deutschland GmbH | Cosmetic basic composition and use thereof |
US20130244976A1 (en) * | 2010-09-24 | 2013-09-19 | Daido Chemical Corporation | Foam-type external skin preparation |
-
2011
- 2011-09-22 US US13/825,404 patent/US20130244976A1/en not_active Abandoned
- 2011-09-22 KR KR1020137010489A patent/KR101729100B1/ko active IP Right Grant
- 2011-09-22 JP JP2012501073A patent/JP5039243B2/ja active Active
- 2011-09-22 EP EP11798298.3A patent/EP2620138B1/en active Active
- 2011-09-22 CN CN201180045432.9A patent/CN103118660B/zh active Active
- 2011-09-22 WO PCT/JP2011/071734 patent/WO2011162421A2/ja active Application Filing
-
2012
- 2012-07-05 JP JP2012151766A patent/JP5181075B2/ja active Active
-
2013
- 2013-01-10 JP JP2013002742A patent/JP2013079282A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60215606A (ja) | 1984-04-12 | 1985-10-29 | Kao Corp | パツク剤 |
JP4248878B2 (ja) | 2001-04-06 | 2009-04-02 | ネオケミア株式会社 | 二酸化炭素外用剤調製用組成物 |
JP2004238333A (ja) | 2003-02-06 | 2004-08-26 | Hiromaito Co Ltd | 炭酸ガス経皮吸収用シート状物及びフェースパック |
Non-Patent Citations (1)
Title |
---|
See also references of EP2620138A4 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013170152A (ja) * | 2012-02-22 | 2013-09-02 | Toyo Aerosol Ind Co Ltd | 泡沫形成エアゾール組成物 |
US20150297475A1 (en) * | 2012-02-29 | 2015-10-22 | Medion Research Laboratories Inc. | Carbon-dioxide-generating cosmetic sheet product |
WO2013129414A1 (ja) * | 2012-02-29 | 2013-09-06 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素を発生する美容シート製品 |
WO2013129413A1 (ja) * | 2012-02-29 | 2013-09-06 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素含有組成物の調製用キット |
CN104039305A (zh) * | 2012-02-29 | 2014-09-10 | 株式会社美迪恩研究实验室 | 含有二氧化碳的组合物的制备用试剂盒 |
CN104135998A (zh) * | 2012-02-29 | 2014-11-05 | 株式会社美迪恩研究实验室 | 产生二氧化碳的美容薄片产品 |
CN104135998B (zh) * | 2012-02-29 | 2017-03-22 | 株式会社美迪恩研究实验室 | 产生二氧化碳的美容薄片产品 |
JPWO2013129413A1 (ja) * | 2012-02-29 | 2015-07-30 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素含有組成物の調製用キット |
JPWO2013129414A1 (ja) * | 2012-02-29 | 2015-07-30 | 株式会社メディオン・リサーチ・ラボラトリーズ | 二酸化炭素を発生する美容シート製品 |
WO2013157034A1 (ja) * | 2012-04-17 | 2013-10-24 | コスメティック・ティエルナ有限会社 | 皮膚外用剤調製用組成物 |
JP2015034132A (ja) * | 2013-08-07 | 2015-02-19 | 大同化成工業株式会社 | 外用剤用組成物 |
JP2015151371A (ja) * | 2014-02-14 | 2015-08-24 | ロレアル | 二酸化炭素を生成し、保持するキット |
JP2015157793A (ja) * | 2014-02-24 | 2015-09-03 | 株式会社ピカソ美化学研究所 | 二酸化炭素発生組成物 |
JP5692618B1 (ja) * | 2014-05-12 | 2015-04-01 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2015214515A (ja) * | 2014-05-12 | 2015-12-03 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2016000712A (ja) * | 2014-05-22 | 2016-01-07 | 株式会社アイビーティジェイ | 二酸化炭素外用剤調製用組成物、その製造方法及び評価方法、並びに二酸化炭素外用剤 |
JP2016008181A (ja) * | 2014-06-23 | 2016-01-18 | 株式会社東洋新薬 | 皮膚外用剤用キット |
US20160067155A1 (en) * | 2014-09-10 | 2016-03-10 | Tadahiro Shimada | Foamable cosmetic product |
JP2016056172A (ja) * | 2014-09-10 | 2016-04-21 | 忠洋 嶋田 | 発泡性の化粧料 |
JP2015214534A (ja) * | 2015-01-21 | 2015-12-03 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2018162289A (ja) * | 2018-06-25 | 2018-10-18 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2018199731A (ja) * | 2018-09-27 | 2018-12-20 | 株式会社東洋新薬 | 皮膚外用剤用キット |
JP2020037587A (ja) * | 2019-11-18 | 2020-03-12 | 株式会社東洋新薬 | 皮膚外用剤用キット |
WO2024141771A1 (en) | 2022-12-30 | 2024-07-04 | L V M H Recherche | Oil-in-water emulsion |
Also Published As
Publication number | Publication date |
---|---|
EP2620138B1 (en) | 2016-12-07 |
JP5181075B2 (ja) | 2013-04-10 |
CN103118660A (zh) | 2013-05-22 |
US20130244976A1 (en) | 2013-09-19 |
JP5039243B2 (ja) | 2012-10-03 |
EP2620138A4 (en) | 2015-10-28 |
EP2620138A2 (en) | 2013-07-31 |
WO2011162421A3 (ja) | 2012-03-08 |
KR101729100B1 (ko) | 2017-04-21 |
JP2012211180A (ja) | 2012-11-01 |
JPWO2011162421A1 (ja) | 2013-08-22 |
JP2013079282A (ja) | 2013-05-02 |
CN103118660B (zh) | 2016-03-16 |
KR20130136994A (ko) | 2013-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5181075B2 (ja) | 発泡型皮膚外用剤 | |
JP6797023B2 (ja) | 過酸化ベンゾイルを含有するすすぎ落とす化学ムース剤 | |
CN106456543B (zh) | 包含过氧化苯甲酰的免洗型化学泡沫 | |
JP2004513958A (ja) | クリーム状のパーマネント泡または安定した発泡クリームの形態である化粧用または皮膚科学用薬剤 | |
JP2014024875A (ja) | ノンガスフォーマー容器入り液体洗浄剤 | |
TW200946141A (en) | Foam-shaped skin liniment | |
CN106456544B (zh) | 包含阿达帕林和过氧化苯甲酰的免洗型化学泡沫 | |
JP5380758B1 (ja) | 二剤式二酸化炭素発生組成物 | |
JP2014141424A (ja) | 外用剤用組成物 | |
KR101490833B1 (ko) | 탄산수가 포접된 폴리머 매트릭스를 유효성분으로 함유하는 클렌저 화장료 조성물 | |
JP2018529772A (ja) | プロピオン酸クロベタゾールを含有する自己発泡性洗浄組成物、及び乾癬の処置におけるその使用 | |
JP4035086B2 (ja) | 泡沫形成化粧料 | |
JP3639987B2 (ja) | ボディ用化粧料 | |
JP2015010054A (ja) | 泡沫状毛髪化粧料 | |
JP2010265214A (ja) | 角質溶解洗浄剤組成物、及び角質溶解洗浄剤 | |
WO2023167114A1 (ja) | 皮膚洗浄剤組成物 | |
JP2005015405A5 (ja) | ||
JP6190258B2 (ja) | 泡沫状毛髪化粧料 | |
JP5648878B2 (ja) | 二剤式二酸化炭素発生組成物 | |
JP2015105246A (ja) | 泡沫状毛髪化粧料 | |
JP2024093105A (ja) | 皮膚洗浄剤組成物 | |
JP2021147355A (ja) | エアゾール型除毛剤 | |
JP2011037756A (ja) | 泡状毛髪化粧料 | |
JPWO2019167837A1 (ja) | 毛髪又は皮膚用洗浄剤組成物 | |
JPWO2008143136A1 (ja) | オクテニルコハク酸トレハロースエステル塩組成物を含有する洗浄剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180045432.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012501073 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11798298 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011798298 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011798298 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137010489 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13825404 Country of ref document: US |